BMC Cancer · 2013 · 15 citations · 32 references
MedicineOncologyPharmacotherapyCancer Drug Toxicity ManagementChemotherapyOncology PharmacotherapyChemotherapy Toxicity ManagementCombination ChemotherapyConcurrent ChemoradiationChemoradiation TrialsComplete Response AssessmentConcurrent Chemoradiation TherapyConcurrent Chemoradiotherapy ToxicityPlatinum-based RegimensTherapy Response Evaluation
BACKGROUND: The purpose of this study was to evaluate the efficacy and tolerability of weekly docetaxel, cisplatin, and S-1 (weekly TPS) as induction chemotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). METHODS: A total of 35 patients with previously untreated, locally advanced HNSCC were enrolled. Seven patients (20%) were diagnosed with stage III HNSCC and 28 patients (80%) were diagnosed with stage IV. Induction treatment included 30 mg/m(2) docetaxel on day 1 and 8, 60 mg/m(2) cisplatin on day 1, and 70 mg/m(2) S-1 on days 1 to 14. The regimen was repeated every 21 days. After three courses of induction chemotherapy, patients received concurrent chemoradiotherapy. RESULTS: Among the 35 patients, 30 (85.7%) completed induction chemotherapy. The response to induction chemotherapy was as follows: nine patients (25.7%) achieved a complete response (CR) and the overall response rate (ORR) was 85.7%. Grades 3-4 toxicity during induction therapy included neutropenia (28.5%), neutropenic fever (8.5%), and diarrhea (17.1%). After completion of concurrent chemoradiotherapy, the CR rate was 62.8% and the partial response (PR) was 22.8%. Estimates of progression-free and overall survival at 2 years were 73.2% and 79.3%, respectively. CONCLUSIONS: Weekly TPS is a promising regimen that is well-tolerated, causes minimal myelosuppression and is effective as an outpatient regimen for locally advanced HNSCC. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01645748.
32
Ahmedin Jemal, Thomas S. Murray, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2005 · 5.5K citations · Full text
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Jan B. Vermorken, Éva Remenár, Carla van Herpen et al. · New England Journal of Medicine · 2007 · 1.7K citations · Full text
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
Marshall R. Posner, Diáne Hershock, C. Blajman et al. · New England Journal of Medicine · 2007 · 1.7K citations · Full text
Medicine, Oncology, Chemotherapy +8